NASDAQ · Medical Instruments & Supplies · USD

Sanara MedTech Inc. (SMTI) Stock Analysis

Sanara MedTech Inc. (SMTI) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SMTI

$32.77

−$0.37 (−1.12%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SMTI with… →

SMTI Key Statistics

As of Oct 21, 2026

Trading

Open: $33.08
Previous Close: $33.14
Day's Range: 32.61–33.08
52-Week Range: 16.05–35.52
Volume: 55.95K
Beta: 1.19

Valuation

Market Cap: $301.09M
P/E Ratio: unprofitable
Forward P/E: 60.69
P/S ratio: 2.74
EPS (ttm): −0.04

Financials (FY)

Revenue (FY): $103.12M+18.97%
Net Income (FY): −$37.56M
Profit margin: −29.15%
Shares Outstanding: 9.19M
1-Year Return: +12.42%

Dividend and dates

Earnings Date: November 11, 2026estimated
Avg Volume: 297.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SMTI closed at $32.77, +12.42% over 1 year.

Sanara MedTech Inc. (SMTI) has a market capitalization of $301.09M.

In fiscal 2025, SMTI reported revenue of $103.12M.

SMTI Stock Return by Calendar Year

Sanara MedTech Inc. (SMTI) 10-year return: what $10,000 became

1 year: $10,000 $11,242; +12.42%
5 years: $10,000 $9,582; −4.18%
10 years: $10,000 $65,540; +555.40%

If you had invested $10,000 in Sanara MedTech Inc. (SMTI) 10 years ago, at the close on October 21, 2016, it would have been worth $65,540 at the close on October 21, 2026: +555.40% in total, +20.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−50.00%+436.67%+40.34%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+40.34%
2025	−29.67%
2024	−19.22%
2023	−9.67%
2022	+53.98%
2021	−40.78%
2020	+209.94%
2019	+436.67%
2018	−50.00%
2017	+50.00%
2016 (partial year)	−20.00%

As of October 21, 2026.

SMTI Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$103.12M	−$37.56M	−36.4%
2024	$86.67M	−$9.66M	−11.2%
2023	$64.99M	−$4.30M	−6.6%
2022	$45.84M	−$7.94M	−17.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$103.12M	$95.60M	$9.15M	−$37.56M	−36.4%
2024	$86.67M	$78.53M	$1.24M	−$9.66M	−11.2%
2023	$64.99M	$57.14M	−$7.67M	−$4.30M	−6.6%
2022	$45.84M	$39.48M	−$12.23M	−$7.94M	−17.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SMTI Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks

Metric	SMTI	Medical Instruments & Supplies median	vs median
P/S ratio	2.74	2.60	6% above
Profit margin	−29.15%	1.62%	30.8 pts below

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Sanara MedTech Inc. (SMTI) at $301.09M. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 108.

The 52-week range on file runs from $16.05 to $35.52. The most recent close on file for SMTI is $32.77, dated October 21, 2026. That is −$0.37 (−1.12%) against the previous close. The latest close sits 104.17% above that 52-week low.

Financial Health

In fiscal 2025, Sanara MedTech Inc. reported revenue of $103.12M. Against the prior fiscal year total of $86.67M, that is a change of +18.97%. The same year closed with a net loss of $37.56M. Profit margin runs at −29.15%. That is 30.8 percentage points below the Medical Instruments & Supplies median of 1.62%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from $45.84M in 2022 to $103.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 60.69. Measured against sales, the shares trade at 2.74 times revenue. On price-to-sales that is 5.55% above the Medical Instruments & Supplies median of 2.6. The medians here are taken across 50 Medical Instruments & Supplies companies that report the metric.

Beta against the wider market is reported at 1.19. Daily returns over the trailing 10 years annualize to a volatility of 109.7%. The trailing one-year total return is +12.42%. Measured over 10 years, that is +20.68% a year compounded.

Growth & Income

No dividend is on file for SMTI.

Across the complete calendar years on file, 2019 returned +436.67% and 2018 returned −50.00%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is +40.34% year to date.

Peer Comparison

Sanara MedTech Inc. (SMTI) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Sanara MedTech Inc.	SMTI	$301.09M	—
Intuitive Surgical, Inc.	ISRG	$151.25B	51.8
Becton, Dickinson and Company	BDX	$52.79B	45.1
Medline Inc.	MDLN	$47.51B	88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Sanara MedTech Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

BDX

Becton, Dickinson and Company

$52.79B

MDLN

Medline Inc.

$47.51B

RMD

ResMed Inc.

$34.63B

ALC

Alcon Inc.

$32.60B

WST

West Pharmaceutical Services, Inc.

$27.69B

View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Sanara MedTech Inc.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Visit website →